Nektar Therapeutics

Nektar Therapeutics is one of biotech's most dramatic reinvention stories. The San Francisco-based company was sitting at a $14B market cap in 2018 on the back of bempegaldesleukin (BMS-986321), an IL-2 cancer immunotherapy that Bristol Myers Squibb licensed for $1.85B upfront and over $1.4B in additional milestones. Then in 2022, after the Phase 3 PIVOT IO-001 trial failure in melanoma, BMS terminated the entire partnership. Nektar's stock collapsed from $24 to under $2.

What survived is more interesting than what failed. The company refocused completely on rezpegaldesleukin (REZPEG), an IL-2 conjugate that selectively expands regulatory T cells (Tregs) — exactly the immunosuppressive direction opposite of the original cancer pivot. Phase 2b data in atopic dermatitis (2024) and Phase 2a in alopecia areata (2025) showed clinically meaningful efficacy, putting REZPEG on track for Phase 3 starts in 2026 across atopic dermatitis, alopecia areata, and ulcerative colitis. The autoimmune TAM is north of $40B annually.

The 2026 stock is consolidating after a 35x rally from 2023 lows. Cash position of $250M provides runway through Q3/2027 — enough to read out two Phase 2 expansions and start one Phase 3 without dilutive financing. Short interest sits at 13.4%, reflecting persistent skepticism about whether a company that already failed its biggest catalyst can pivot to autoimmune leadership.

Nektar's institutional ownership has rotated almost completely since 2022. The pre-BMS-failure shareholder base (large generalist mutual funds) has been replaced by specialty biotech crossover funds with conviction in the IL-2-Treg pivot. Baker Brothers Advisors opened a 5.4% position in Q3/2024 at sub-$3 levels and has held throughout the 25x rally. Adage Capital Partners (Boston-based fundamental specialist) sits at 3.8%. OrbiMed Advisors holds 3.1% and added in Q4/2025.

The most interesting bull signal is Perceptive Advisors (Joe Edelman), which historically takes its biggest positions in autoimmune-pipeline assets — Perceptive opened 4.2% in Q1/2026. Combined, the top-3 dedicated biotech holders (Baker, Adage, Perceptive) own approximately 13.5% — a level of concentration that typically signals a credible takeout floor.

On the bear side, D. E. Shaw reported a short position in their European disclosure equivalent, and the 13.4% short interest reflects the post-bempegaldesleukin skepticism. Days-to-cover at 5.2x — a credible squeeze setup if REZPEG Phase 2b alopecia areata long-term data (expected Q3 2026) shows durable hair regrowth above 70% SALT-50 response.

Insider activity is mixed: CEO Howard Robin (longtime CEO, in post since 2003) has not sold any shares since the bempegaldesleukin failure — unusually patient signal. CFO Sandra Gardiner exercised options in February 2026 but kept all underlying shares.

Nektar trades at an enterprise value of approximately $2.1B (market cap $2.4B - $250M cash + minimal debt). Standard P/E is irrelevant given negative margins. Biotech option pricing: REZPEG atopic dermatitis risk-adjusted NPV $2.4B (40% PoS at $3.5B peak sales), alopecia areata $1.0B (35% PoS at $1.2B peak), ulcerative colitis $0.6B (20% PoS at $1.5B peak), platform optionality $0.5B, less $0.6B operating burn through Phase 3 — sums to $3.9B target market cap vs current $2.4B. The sell-side mean target of $153 (8 analysts) implies 117% upside from $71. The bear case (REZPEG Phase 3 fails in AD, similar to bempegaldesleukin) takes Nektar back to cash-shell value of $5-8. The asymmetry remains favorable, but position sizing should reflect the binary nature: half-position with adds only after Phase 3 starts in Q3/2026.

1. Q3 2026 (estimated): REZPEG Phase 3 atopic dermatitis (REZOLVE-AD3) trial start — confirms commercialization timeline
2. Q3 2026 (estimated): REZPEG Phase 2b alopecia areata long-term durability data — supports Phase 3 design in 2027
3. Q4 2026 (estimated): REZPEG Phase 2 ulcerative colitis interim readout — first expansion beyond skin indications

Nektar Therapeutics is the kind of contrarian biotech setup that requires either tolerating significant binary risk or sitting it out completely. The combination of Baker Brothers concentration (5.4%), management cost discipline post-bempegaldesleukin failure, and a clear REZPEG Phase 3 path is compelling. But the same management team failed bempegaldesleukin spectacularly in 2022 — the risk that REZPEG produces similar Phase 3 disappointment cannot be dismissed. My approach: 1% portfolio position only, with a pre-committed plan to add 1% if Phase 2b alopecia areata long-term durability data exceeds 60% SALT-50 at week 52, and to exit completely if REZPEG Phase 3 AD trial design includes any unexpected primary endpoint compromise. This is a 12-24 month Phase 3 setup trade, not a buy-and-hold compounder.